Slow Parkinson progression with glucoraphanin
- Trial ID
- NCT07360977
- Official Title
- A Composition Comprising Glucoraphanin, Myrosinase and a Buffered Solution for Use in the Treatment of Neurodegenerative Diseases
- Goal
- Slow Parkinson progression with glucoraphanin
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- IRCCS Centro Neurolesi Bonino Pulejo
- Study Type
- INTERVENTIONAL
- Enrollment
- 300 participants
- Conditions
- PARKINSON DISEASE (Disorder), Multiple Sclerosis (MS) - Relapsing-remitting, Pediatric Patients Affected by Neuromuscolar and Degenerative Diseases
- Interventions
- bioactivated GRA for adult patients, bioactivated GRA for pediatric patients
Plain-Language Summary
The goal is to reduce nerve cell damage from oxidative stress and inflammation that can drive Parkinson's progression, with the hope of protecting neurons and slowing decline. The approach gives bioactivated GRA, a mix of glucoraphanin plus myrosinase in a buffered solution that converts to sulforaphane in the body and activates the Nrf2 antioxidant and detox pathways, and it is intended to be used alongside stable anti-parkinsonian meds rather than replace levodopa. Enrollment includes several groups, notably people with Parkinson's aged 45 to 75 meeting UK Brain Bank criteria who have had stable anti-parkinsonian treatment for at least three months, adults with relapsing-remitting MS, and clinically stable pediatric patients aged 1 to 10 who weigh 5 to 30 kg. People with MRI contraindications, significant cognitive impairment (MMSE <24), major comorbidities, pregnancy, or recent changes in treatments are excluded.
Locations
- IRCCS Centro Neurolesi Bonino Pulejo, Messina, Italy
Frequently Asked Questions
- What is this trial testing?
- This trial is studying bioactivated GRA for adult patients. The goal is to reduce nerve cell damage from oxidative stress and inflammation that can drive Parkinson's progression, with the hope of protecting neurons and slowing decline. The approach gives bioactivated GRA, a mix of glucoraphanin plus myrosinase in a buffered solution that converts to sulforaphane in the body and activates the Nrf2 antioxidant and detox pathways, and it is intended to be used alongside stable anti-parkinsonian meds rather than replace levodopa. Enrollment includes several groups, notably people with Parkinson's aged 45 to 75 meeting UK Brain Bank criteria who have had stable anti-parkinsonian treatment for at least three months, adults with relapsing-remitting MS, and clinically stable pediatric patients aged 1 to 10 who weigh 5 to 30 kg. People with MRI contraindications, significant cognitive impairment (MMSE <24), major comorbidities, pregnancy, or recent changes in treatments are excluded.
- Who can participate?
- Participants must be between 1 Year and 75 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 5 months.